NCT03872921View on ClinicalTrials.gov

norUrsodeoxycholic Acid vs Placebo in PSC

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

February 8, 2018

Primary Completion Date

January 31, 2025

Study Completion Date

June 30, 2026

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

norUrsodeoxycholic Acid

oral treatment

Trial Locations (2)

1090

Medical University of Vienna, Department of Internal Medicine III, Vienna

30623

Medical School Hannover, Hanover

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY